Fig. 5.
The effect of mu-adecatumumab and adecatumumab on lung tumor colony formation in immunocompetent mice. B16/EpCAM cells (1 × 105) were intravenously injected into C57BL/6 mice and animals treated three times a week with the indicated doses of adecatumumab, mu-adecatumumab or human IgG1 control antibody starting 1 h after intravenous B16/EpCAM cell injection. Mice were sacrificed on day 26 after B16/EpCAM cell injection. a Lungs were filled with tissue teck and digital photographs taken. b The number of lung tumor colonies was determined macroscopically. While symbols indicate the number of lung colonies for one single mouse, the black bar indicates means of each group. Asterisks indicate statistical differences between treatment and isotype control group (**P ≤ 0.01 as determined with Student’s t-test)